Moreover, the Authors demonstrated low miR-26a levels as an independent predictor of shorter survival in a HBV-related HCC patients’ cohort and showed the predominant activation of the NF-κB/IL-6 signaling pathway in the low miR-26a HCCs subgroup, which had, however, a favorable response to interferon-α adjuvant therapy [34]. This evidence concerns the gene IL6 and hepatocellular carcinoma.